Side-by-side
Pick up to 3 peptides and see their key facts side by side. Useful for narrowing a search before deciding which page to read in full.
1 of 3 selected.
| Field | Last updated |
|---|---|
| Aliases | Trelstar, Decapeptyl, triptorelin pamoate, triptorelin acetate, GnRH agonist |
| Category | Other Research Peptides |
| Formula | C₆₄H₈₂N₁₈O₁₃ |
| Molecular weight | 1311.45 Da |
| Half-life | ~7–15 min (free); 22–28 days (depot) |
| Mechanism (summary) | Triptorelin is a GnRH agonist FDA-approved as TRELSTAR for advanced prostate cancer. Non-U.S. labeling extends use to endometriosis, fibroids, hormone-responsive breast cancer, infertility protocols, and central precocious puberty (Decapeptyl). |
| Dosing notes | TRELSTAR: 3.75 mg every 4 weeks, 11.25 mg every 12 weeks, or 22.5 mg every 24 weeks for prostate cancer. Outside the U.S., Decapeptyl formulations include 1-month, 3-month, and 6-month schedules for prostate disease, endometriosis, central precocious puberty, and other indications depending on product and jurisdiction. |
| Storage | TRELSTAR: store at 20–25 °C; do not freeze. European Decapeptyl labeling: do not store above 25 °C; administer immediately after reconstitution. |
|---|
| Read more | Full reference → |
|---|